Intended Audience: Managed care pharmacy directors, medical directors, pharmacists, and medication therapy management nursing directors

While anti-VEGF therapies have been the mainstay for treating age-related macular degeneration (AMD) and diabetic macular edema (DME) for over a decade, new clinical and real-world data continue to emerge on their relative efficacies and various treatment approaches. Novel therapies are also emerging with differing mechanisms of action, unique delivery methods, and extended dosing strategies that promise to reduce treatment burden while enhancing vision benefits.

Join expert faculty for this accredited session, presented in partnership with an AMCP chapter affiliate, as they examine new evidence and discuss implications for managed care decision-making to optimize outcomes for patients with AMD or DME.

Funding Disclosure
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Genentech.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.